Free Newsletter
SPOTLIGHT: GSK's Arixtra losing to Rivaroxaban
Free newsletter via e-mail
Tools
A research report concludes that GlaxoSmithKline's anti-clotting drug Arixtra is losing ground to Rivaroxaban, made and marketed by Bayer Schering/Johnson & Johnson. Released by Decision Resources, the report cites Arixtra's need for close monitoring and its potential for serious side effects such as hemorrhage. Article
More stories about GlaxoSmithKline
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: